Resultados globales: 1 registros encontrados en 0.02 segundos.
Artículos, Encontrados 1 registros
Artículos Encontrados 1 registros  
1.
10 p, 1.8 MB Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma : Updated Overall Survival, Safety, and Subgroups / Orlowski, Robert Z. (Department of Lymphoma and Myeloma. The University of Texas M.D. Anderson Cancer Center) ; Moreau, Philippe (Department of Hematology. University Hospital Hotel-Dieu) ; Niesvizky, Ruben (Department of Medical Oncology. Myeloma Center. New York Presbyterian Hospital-Weill Cornell Medical Center) ; Ludwig, Heinz (Wilhelminen Cancer Research Institute (Viena, Àustria)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Chng, Wee Joo (Department of Hematology Oncology. National University of Singapore) ; Goldschmidt, Hartmut (Department of Hematology Oncology. Heidelberg University Clinic and the National Center of Tumor Diseases) ; Yang, Zhao (Department of Biostatistics. Amgen. Inc) ; Kimball, Amy S. (Department of Clinical Research. Amgen. Inc) ; Dimopoulos, Meletios (Department of Clinical Therapeutics. University Athens School of Medicine) ; Universitat Autònoma de Barcelona
Introduction: The phase III RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma (ENDEAVOR) trial showed significantly improved progression-free survival and overall survival (OS) with carfilzomib (56 mg/m) and dexamethasone (Kd56) versus bortezomib and Kd56 (Vd) in patients with relapsed or refractory multiple myeloma (RRMM). [...]
2019 - 10.1016/j.clml.2019.04.018
Clinical Lymphoma, Myeloma & Leukemia, Vol. 19 Núm. 8 (august 2019) , p. 522-530.e1  

Vea también: autores con nombres similares
1 Kimball, Alexa B.
1 Kimball, Alexandra B.
1 Kimball, Amy S.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.